In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa

Journal of Infectious Diseases

Volumn 199, Issue 5, 2009, Pages 750-757

  Sisowath, Christin ^a,e   Petersen, Ines ^d   Veiga, M Isabel ^a,b   Mårtensson, Andreas ^a   Premji, Zul ^c   Björkman, Anders ^a   Fidock, David A ^d   Gil, José P ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^d Columbia University ^*  (United States)

^e Malaria Research   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; FANSIDAR;

AFRICA; ALLELE; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; FOLLOW UP; GENE; GENE AMPLIFICATION; GENOTYPE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PFCRT GENE; PFMDR 1 GENE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RECURRENT INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MEMBRANE TRANSPORT PROTEINS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PYRIMETHAMINE; SELECTION (GENETICS); SULFADOXINE;

EID: 61849097741     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596738     Document Type: Article

References (41)

1. Martensson A, Strömberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005; 41:1079-86.
2. Martensson A, Ngasala B, Ursing J, et al. Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. J Infect Dis 2007; 195:597-601.
3. Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007; 45:1453-61.
4. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403:906-9.
5. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol 2005; 57:913-26.
6. Anderson TJ, Nair S, Qin H, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother 2005; 49:2180-8.
7. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 2000; 108:13-23.
8. Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42:1570-7.
9. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-47.
10. Uhlemann AC, Ramharter M, Lell B, Kremsner PG, Krishna S. Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis 2005; 192:1830-5.
11. Sisowath C, Strömberg J, Mårtensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemetherlumefantrine (Coartem). J Infect Dis 2005; 191:1014-7.
12. Sisowath C, Ferreira PE, Bustamante LY, et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 2007; 12:736-42.
13. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 2006; 50:1893-5.
14. Humphreys GS, Merinopoulos I, Ahmed J, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 2007; 51:991-7.
15. Hastings IM, Ward SA. Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis 2005; 192:1303- 4; author reply, 1304-5.
16. Hayward R, Saliba KJ, Kirk K. pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol Microbiol 2005; 55:1285-95.
17. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861-71.
18. Djimdé A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344:257-63.
19. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002; 298:210-3.
20. Lakshmanan V, Bray PG, Verdier-Pinard D, et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J 2005; 24:2294-305.
21. Cooper RA, Ferdig MT, Su XZ, et al. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol Pharmacol 2002; 61:35-42.
22. Johnson DJ, Fidock DA, Mungthin M, et al. Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell 2004; 15:867-77.
23. Veiga MI, Ferreira PE, Björkman A, Gil JP. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol Cell Probes 2006; 20:100-4.
24. Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 1998; 54:1140-7.
25. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27:594-601.
26. Wellems TE, Panton LJ, Gluzman IY, et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 1990; 345:253-5.
27. World Health Organization. Treatment policies. Available at: http://www.who.int/malaria/treatmentpolicies.html. Accessed 20 May 2008.
28. Rohrbach P, Sanchez CP, Hayton K, et al. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J 2006; 25:3000-11.
29. Volkman SK, Cowman AF, Wirth DF. Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1995; 92:8921-5.
30. Michaelis S. STE6, the yeast α-factor transporter. Semin Cell Biol 1993; 4:17-27.
31. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005; 94:181-90.
32. Karcz SR, Galatis D, Cowman AF. Nucleotide binding properties of a P-glycoprotein homologue from Plasmodium falciparum. Mol Biochem Parasitol 1993; 58:269-76.
33. Barnes DA, Foote SJ, Galatis D, Kemp DJ, Cowman AF. Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J 1992; 11:3067-75.
34. Price RN, Cassar C, Brockman A, et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 1999; 43:2943-9.
35. Pickard AL, Wongsrichanalai C, Purfield A, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003; 47:2418-23.
36. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320:330-4.
37. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 2008; 14:716-9.
38. Kublin JG, Cortese JF, Njunju EM, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 2003; 187:1870-5.
39. Mita T, Kaneko A, Lum JK, et al. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 2003; 68:413-5.
40. Mita T, Kaneko A, Lum JK, et al. Expansion of wild type allele rather than back mutation in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium falciparum in Malawi. Mol Biochem Parasitol 2004; 135:159-63.
41. Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006; 355:1959-66.